Bristol Myers Squibb (NYSE: BMY; BMS) beat analyst consensus forecasts by reporting higher than expected numbers for total revenue and its “growth” portfolio of drugs on which BMS is counting on for ...
Bristol Myers Squibb on Thursday forecast 2026 revenue and profit above Wall Street estimates, saying that price cuts to its blood thinner Eliquis will help drive up revenue, and shares of the U.S ...
Investing.com - Bristol Myers Squibb has posted fourth-quarter earnings and revenue which topped estimates, fueled by solid ...
While apixaban was linked to more total major bleeds, rates of fatal and intracranial hemorrhage were similar to aspirin.
Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced an agreement with the U.S. government to provide Eliquis® (apixaban), an oral anticoagulant relied upon by millions of Americans daily, for free ...
TAIPEI, Oct. 1, 2025 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. ("TAHO Pharma") today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...
Eliquis Offered to Cash-Paying Patients at More Than 40% Discount to Current List Price, Sotyktu at More Than 80% Discount to Current List Price PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...
On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...
Bristol Myers Squibb's "BMS Patient Connect" platform offers Sotyktu at over 80% less than the list price, enhancing accessibility for psoriasis patients. Eliquis, an anticoagulant, is available at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results